RESEARCH ARTICLE


Destructive Dural Ectasia of Dorsal and Lumbar Spine with Cauda Equina Syndrome in a Patient with Ankylosing Spondylitis



Marijke Van Hoydonck, Kurt de Vlam, Rene Westhovens, Frank P Luyten , Rik J Lories*
Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000, Leuven, Belgium


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 3326
Abstract HTML Views: 1681
PDF Downloads: 577
Total Views/Downloads: 5590
Unique Statistics:

Full-Text HTML Views: 1749
Abstract HTML Views: 1065
PDF Downloads: 431
Total Views/Downloads: 3250



Creative Commons License
© Van Hoydonck et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Division of Rheumatology, University Hospitals Leuven, Herestraat 49, B-3000, Leuven, Belgium; Tel: +32-16-342541; Fax: +32-16-342543; E-mail: Rik.Lories@uz.kuleuven.be


Abstract

We present a patient with longstanding ankylosing spondylitis complicated with cauda equina syndrome. The patient suffered from increasing pain in the leg with reduced sensitivity and extremely cold feet associated with incontinence. Diagnostic workup revealed dural ectasia, arachnoiditis and a spinal inflammatory mass leading to extensive vertebral bone destruction. Of interest, this was not only found in the lumbar spine region (which is typical in cases of cauda equina syndrome associated with ankylosing spondylitis) but also in the lower cervical spine (C7) and upper dorsal spine. Moreover, the bone destructive phenotype of this complication of long-standing AS contrasts with the usual characteristics of new bone formation and ankylosis. As initial treatment with anti-inflammatory drugs was not sufficiently successful, infliximab therapy was started which resulted in manifest clinical improvement as chronic pain, incontinence and laboratory signs of inflammation progressively disappeared.

Keywords: Ankylosing spondylitis, cauda equina syndrome, bone destruction, anti-TNF..